Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
Rhea-AI Summary
Artiva Biotherapeutics (Nasdaq: ARTV) will present at the 2026 Transplantation & Cellular Therapy Tandem Meetings in Salt Lake City, Feb 4–7, 2026. Artiva will feature poster presentations on Feb 5, 2026 at 6:30 pm MST covering: the cost-effectiveness of AB-101/AlloNK administered in an outpatient community rheumatology practice versus CAR-T treatments, and continued durability data for AlloNK in relapsed/refractory Non-Hodgkin Lymphoma from a multi-center Phase 1/2 trial. Poster IDs are 440 (health services/cost-effectiveness) and 511 (lymphoma clinical durability); authors listed include Nicholas Veomett, Ph.D. and Umer Farooq, M.D. For full abstracts, consult the 2026 Tandem Meetings program.
Positive
- None.
Negative
- None.
News Market Reaction – ARTV
On the day this news was published, ARTV gained 2.81%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $125M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ARTV gained 4.52% with mixed peer action: ALXO +13.79%, VANI +3.82%, while INKT, CELU, and ACET declined. Only VANI appeared on the momentum scanner, suggesting a stock-specific move for ARTV rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Leadership change | Positive | -0.4% | New CEO appointed to advance intracellular medicines platform. |
| Nov 12 | Clinical data update | Positive | +10.9% | Positive initial safety and B-cell depletion data for AlloNK in autoimmune. |
| Nov 12 | Earnings and pipeline | Positive | +10.9% | Q3 2025 results plus Fast Track designation and >100 patients treated. |
| Nov 03 | Data event preview | Neutral | -9.6% | Announcement of virtual event to discuss initial AlloNK safety data. |
| Oct 30 | Investor conferences | Neutral | -10.3% | Participation in November investor conferences with webcast access. |
Positive clinical and corporate updates (e.g., AlloNK data, Q3 results) have often coincided with strong upside, while conference/meeting announcements show more variable reactions.
Over the past six months, Artiva has highlighted AlloNK’s progress across autoimmune and oncology settings, including positive safety and B-cell depletion data in 32 patients and an FDA Fast Track designation for refractory rheumatoid arthritis. Q3 2025 results showed a cash position of $123.0M and runway into Q2 2027. Conference and investor-event announcements in late 2025 drew mixed price reactions. Today’s Tandem Meetings poster news extends the theme of showcasing AlloNK’s clinical durability and real-world feasibility rather than introducing new topline data.
Regulatory & Risk Context
An S-3 shelf registration filed on 2025-08-06 remains active through 2028-08-06 with no recorded usage to date, indicating registered capacity for future securities offerings but no executed takedowns in the provided period.
Market Pulse Summary
This announcement highlights upcoming 2026 Tandem Meetings posters on AlloNK’s cost-effectiveness in community rheumatology settings and durability in NHL, reinforcing its outpatient and real-world positioning. In late 2025, Artiva reported positive AlloNK data, an FDA Fast Track designation, and cash of $123.0M with runway into Q2 2027. Investors tracking this program have previously focused on concrete clinical outcomes and regulatory milestones, making subsequent efficacy, safety, and pivotal trial design updates key items to watch.
Key Terms
nk cell therapy medical
car-t treatments medical
phase 1/2 medical
non-hodgkin lymphoma medical
rituximab medical
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).
The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings:
| Poster ID: 440 | AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases |
| Poster Session: | Health Services and Barriers to Access |
| Date / Time: | Thursday, February 5, 2026, at 6:30 pm MST |
| Author: | Nicholas Veomett, Ph.D., Vice President, Corporate Development, Artiva Biotherapeutics |
| Poster ID: 511 | A Multi-Center, Phase 1/2 Trial of AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non‑Hodgkin Lymphoma |
| Poster Session: | Lymphoma – Clinical |
| Date / Time: | Thursday, February 5, 2026, at 6:30 pm MST |
| Author: | Umer Farooq, M.D., Clinical Professor of Internal Medicine-Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa |
For more information on these abstracts, visit the 2026 Tandem Meetings website.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (the “Tandem Meetings”), Artiva Biotherapeutics, Inc.’s (the “Company”) participation at the Tandem Meetings, and the Company’s mission, product candidates (including their potential to be cost effective, administrability in a community rheumatology practice, and durability), clinical trials, pipeline, and strategic partnerships. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
FAQ
What will Artiva (ARTV) present at the 2026 Tandem Meetings on February 5, 2026?
Which Artiva poster discusses cost-effectiveness of AlloNK versus CAR-T for rheumatologic diseases?
Which Artiva poster reports durability of AlloNK in Non-Hodgkin Lymphoma (NHL)?
Who are the listed authors for Artiva's 2026 Tandem Meeting posters (ARTV)?
How can investors view Artiva's abstracts for the 2026 Tandem Meetings (ARTV)?
